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Abstract
Aims/hypothesis The aim of this study was to assess the role
of socioeconomic status (SES) in the associations between
type 2 diabetes and life expectancy in a complete national
population.
Methods An observational population-based cohort study
was performed using the Scottish Care Information –
Diabetes database. Age-specific life expectancy (stratified by
SES) was calculated for all individuals with type 2 diabetes in
the age range 40–89 during the period 2012–2014, and for the
remaining population of Scotland aged 40–89 without type 2
diabetes. Differences in life expectancy between the two
groups were calculated.
Results Results were based on 272,597 individuals with type
2 diabetes and 2.75 million people without type 2 diabetes
(total for 2013, the middle calendar year of the study period).
With the exception of deprived men aged 80–89, life expec-
tancy in people with type 2 diabetes was significantly reduced
(relative to the type 2 diabetes-free population) at all ages and
levels of SES. Differences in life expectancy ranged from
−5.5 years (95% CI −6.2, −4.8) for women aged 40–44 in
the second most-deprived quintile of SES, to 0.1 years (95%
CI −0.2, 0.4) for men aged 85–89 in the most-deprived quin-
tile of SES. Observed life-expectancy deficits in those with
type 2 diabetes were generally greater in women than in men.
Conclusions/interpretation Type 2 diabetes is associated with
reduced life expectancy at almost all ages and levels of SES.
Elimination of life-expectancy deficits in individuals with type
2 diabetes will require prevention and management strategies
targeted at all social strata (not just deprived groups).
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Introduction
The elevation of mortality risk associated with diabetes is well
established [1, 2]; one meta-analysis has concluded that mor-
tality in diabetic populations is approximately double that
observed in those without diabetes [3], while a Scottish study
found that the relative risk of mortality associated with type 2
diabetes compared with a diabetes-free population was 1.35 for
men and 1.62 for women [4]. A number of studies have
expressed the excess risk of death associated with diabetes in
terms of differential life expectancy [5–14]; that is, the mean
number of expected additional years of life at specific ages
under the assumption that current observed mortality rates
remain unchanged throughout the lives of the population of
interest. However, few investigations have focused exclusively
on type 2 diabetes; rather, studies have tended either not to
differentiate between type 1 and type 2 disease [5, 7–9, 13],
or to concentrate exclusively on the former [10–12]. A further
limitation of work in this area is that although the association
between diabetes and mortality appears to be modified by
socioeconomic status (SES) [4], and life expectancy in general
populations has been found to vary by SES [15, 16], few studies
investigating relationships between diabetes and life expectan-
cy have explicitly sought to assess how these relationships are
linked to SES. Rather, SES (where it is considered at all) has
generally been treated as a potential confounder which may
obscure associations between diabetes and the expectation of
life. One exception to this is work reported by Perna et al [17],
which found that SES-related differences in life expectancy
increased when diabetes was present. Because the prevalence
of diabetes is higher in deprived groups [18, 19], and mortality
risk within diabetic populations (as in general populations) is
known to vary by SES [4, 20–22], it is important to estimate the
role (not necessarily causal) of SES in the observed associations
between the presence of diabetes and life expectancy.
Understanding that role will help to clarify whether apparent
differences in life expectancy between groups with and without
diabetes wholly or partly reflect varying patterns of SES rather
than differential diabetes status. The study reported here
examined the relationships among these three factors, diabetes,
SES, and life expectancy, with two objectives, namely (1) to
ascertain whether differences in life expectancy associated with
type 2 diabetes are present at all levels of SES and to quantify
these differences; and (2) to determine whether patterns of SES-
related differences in life expectancy among people with type 2
diabetes are similar to those observed in a general population.
Methods
Data sources and study population The overall design of the
study was based on deriving period life tables for (1) a cohort of
people with type 2 diabetes, and (2) the remainder of the
population of Scotland that does not have type 2 diabetes, per-
mitting the respective life expectations of these two groups to be
compared. To create the type 2 diabetes cohort, all individuals
living with type 2 diabetes in Scotland at any point during the
period 1 January 2012 to 31 December 2014 were identified
from the Scottish Care Information – Diabetes (SCI-Diabetes)
dataset [23]. SCI-Diabetes is a national register of people with
diabetes who are resident in Scotland. Initially developed as a
system to aid clinical management of individuals with diabetes,
SCI-Diabetes has been extensively used in support of diabetes-
related epidemiological research (with appropriate controls to
protect patient confidentiality and privacy). The study reported
here used data extracted from SCI-Diabetes in 2016. SCI-
Diabetes data are available from the Health Informatics Centre
at the University of Dundee but restrictions apply to the
availability of these data, which were used under license for
the current study, and so are not publicly available. Data are,
however, available with permission of the Public Benefit and
Privacy Panel for Health and Social Care of National Health
Service National Services Scotland (NHSNSS). The SCI-
Diabetes data were linked to national mortality records by the
Information Services Division (ISD) of NHSNSS, thus
allowing the vital status of individuals included in the study to
be determined throughout the study period. Generation of the
linked dataset was approved by the responsible ethics commit-
tee, Caldicott guardians and the NHSNSS Privacy Application
Committee (application no. 33/11). The data were anonymised
prior to the researchers being granted access.
Statistical analysis Numbers of person-years and of deaths
contributed by the cohort of individuals with type 2 diabetes
during the three-year study period were summed, and aggre-
gated by age and SES. The measure of SES used was the
Scottish Index of Multiple Deprivation (SIMD) [24]. This is
a small-area-based ranked measure which combines 38 indica-
tors of deprivation across seven different conceptual domains,
and is recognised by the Scottish Government as the standard
method of assessing deprivation in Scotland. For the purposes
of this investigation, rankings of the 6505 geographical areas
recorded in the SIMDwere expressed as quintiles (the first and
fifth quintiles representing the most- and least-deprived groups
in the population, respectively). Numbers of person-years and
of deaths accrued by the type 2 diabetes cohort were subtracted
frommid-year population totals and overall numbers of deaths
in Scotland, these national data again being supplied by ISD
and aggregated by age and SES (quintile of the SIMD). This
subtraction operation generated the comparison group
(referred to hereafter as the ‘type 2 diabetes-free population’),
from which person-years and deaths contributed by people
with type 2 diabetes had been removed. This approach avoids
the inadvertent introduction of bias from selection of a limited
number of controls. Because the studywas conceived as a strict
comparison between groups with and without type 2 diabetes,
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the type 2 diabetes-free population retained a small number of
individuals with type 1 diabetes. However, the effect of these
people on life expectancy in the type 2 diabetes-free population
is expected to be small, because type 1 disease is uncommon
(relative to total population size) in the age range covered by
the study (40–89 years).
For both the type 2 diabetes cohort and the type 2 diabetes-
free population, abridged life tables as described byChiang [25]
were constructed to generate life-expectancy estimates.
Creation of the life tables was achieved by adapting an Excel
template published by the UKOffice of National Statistics [26].
Operation of the template was verified using an S-language
routine for generating life tables published by Selvin [27]; both
approaches yielded identical results. Because type 2 diabetes is
rare in younger adults, and elderly people are subject to a wide
range of mortality risks beyond those specifically associated
with diabetes, life-expectancy values were reported only for
the age range 40–89 years (in five-year intervals: 40–44, 45–
49, 50–54... ...80–84, 85–89). Five-year intervals are conven-
tionally chosen for life-table approaches because of the expo-
nential, rapidly changing effect of increasing age on life expec-
tancy. Stratification by age is used to investigate the presence or
absence of interactions, in this case with both diabetes status
and SES. Unlike regression-model-based analyses, the life-
table approach does not allow formal tests for interaction
(which can also be difficult to interpret when there are multiple
interactions as in this case between type 2 diabetes, age, sex and
SES). We have used figures to illustrate how SES affects the
association between type 2 diabetes and life expectancy.
Results were derived separately for each sex, yielding a total
of 100 paired life-expectancy values (two sexes × five SES
strata × ten age intervals). Each pair of values consisted of
two elements: the estimated life expectancy for the type 2 dia-
betes cohort, and the corresponding value for the type 2
diabetes-free population. Paired values were also expressed as
the difference between the estimated life expectancy for the
type 2 diabetes cohort and that for the type 2 diabetes-free
population, calculated as the former minus the latter. Thus,
negative difference values indicated a lower expectation of life
in people with type 2 diabetes. CIs around life-expectancy
values, and around differences in life-expectancy values, were
calculated using the methods described by Chiang [25].
Although the study period was defined as 2012–2014, all analy-
ses were repeated for the period 2004–2006 with the aim of
informally assessing whether the main findings of interest were
materially different for this earlier time interval.
Results
Results were based on 272,597 individuals with type 2 diabe-
tes and approximately 2.75 million people without type 2
diabetes, the latter total being that for the year 2013 (the
middle calendar year of the study period). Over the three-
year study period, numbers of person-years accrued for the
type 2 diabetes cohort in the age range of interest (40–89 years)
were 390,567 (men) and 306,872 (women). Corresponding
numbers of deaths were 13,875 (men) and 11,471 (women).
For the type 2 diabetes-free population, numbers of person-
years in the target age range were 3,509,683 (men) and
4,034,066 (women). Numbers of deaths in the type 2
diabetes-free population were 53,711 (men) and 53,705
(women). Table 1 summarises results without stratification
by SES in order to illustrate the overall effects of type 2 dia-
betes on life expectancy.
Table 1 presents, for each combination of sex and age in-
terval, the numbers of person-years and of deaths in both
cohorts; observed mortality rates; estimated life-expectancy
values (with 95% CI); and the difference in life expectancy
between the type 2 diabetes cohort and the type 2 diabetes-free
population (with 95% CI). The results show that type 2 dia-
betes is associated with lower life expectancy at all ages and
that difference in life expectancy between people with and
without type 2 diabetes is greater at younger than older ages
and for women than men. Values of life expectancy for both
groups (with stratification by SES) are shown graphically in
Fig. 1a and 1b for men and women respectively with data
given in ESM Tables 1–5 in the supplementary material.
Differences in life expectancy between those with type 2
diabetes and the corresponding stratum in the type 2 diabetes-
free population are presented in Fig. 2a and b for men and
women respectively. In addition to the patterns by age demon-
strated in Table 1, these figures demonstrate that SES also
influences life expectancy, with the smallest differences in life
expectancy betweenmenwith andwithout diabetes observed in
themost-deprived fifth of the population (identified as Q1 in the
figures).
Differences in life expectancy (negative values indicating
reduced expectancy of life in those with type 2 diabetes)
ranged from 0.1 years (−0.2 years to 0.4 years) for men aged
85–89 in the most-deprived quintile of SIMD to −5.5 years
(−6.2 years to −4.8 years) for women aged 40–44 in the
second most-deprived quintile of SIMD. There were only
two instances among the 100 calculated life-expectancy
differences for which the 95% CI was found to include the
value zero (interpreted as insufficient evidence to conclude
that a statistically significant difference in life expectancy
exists between those with type 2 diabetes and those without),
and these occurred among the most-deprived fifth of men in
the 80–84 and 85–89 year age groups. For all remaining life-
expectancy value pairs, the 95% CI around the difference
excluded zero: the intervals were strictly negative, indicating
statistically significant differences.
The study’s second objective—assessing whether SES-
related differences in life expectancy in the type 2 diabetes
cohort were similar to those in the type 2 diabetes-free
110 Diabetologia (2018) 61:108–116
population—was pursued by calculating the difference be-
tween the respective life-expectancy values for people in the
most- and least-deprived SIMD quintiles for each combina-
tion of cohort, sex and age interval (40 strata in total). This
quantity may be viewed as an approximation to the gradient of
SES-related differences in life expectancy (assuming a broad
linearity in the association between life expectancy and SES
within each stratum). These differences are presented in Fig.
3a and b for men and women respectively, which show that
life expectancy is lower for people in the most- compared with
the least-deprived fifths of the population for almost all age
groups regardless of type 2 diabetes status, with the exception
of men of 85–89 years of age with type 2 diabetes. The dif-
ference in life expectancy between people in the most- and
least-deprived fifths of the population is greater at younger
than older ages and for men without type 2 diabetes than for
men with type 2 diabetes; the effect of deprivation on life
expectancy was similar in women with and without type 2
diabetes.
Discussion
This is believed to be the first study investigating the life-
expectancy deficit associatedwith type 2 diabetes in a complete
national population to focus specifically on the potential role of
SES (an accepted determinant of mortality risk in both diabetic
and general populations). The study’s first objective was to
ascertain whether differences in life expectancy associated with
type 2 diabetes are present at all levels of SES and to quantify
any such differences. The findings indicate that, with the
exception of deprived elderly men (most-deprived SIMD quin-
tile; ages 80–84 and 85–89), life expectancy in those with type
2 diabetes is significantly lower than that in the type 2 diabetes-
free population at all ages and levels of SES. While persistence
of a life expectancy deficit across the full range of deprivation
levels is confirmed, it is clear that the magnitude of the
differences in life expectancy between those with and without
type 2 diabetes is not uniform. A marked distinction by sex is
evident: type 2 diabetes-related differences in life expectancy
Table 1 Abridged life table for men and women with type 2 diabetes vs population of Scotland without type 2 diabetes; period 2012–2014
Observed data in type 2
diabetes cohort
Observed data in type 2
diabetes-free population
Estimated life expectancy (95% CI)
Age interval
(years)
Person-
years
Deaths Death rate per
1000 P-Y
Person-years Deaths Death rate per
1000 P-Y
Type 2 diabetes
cohort
Type 2 diabetes-free
population
LE differencea
Men
40–44 12,858 64 5.0 529,939 1305 2.5 35.3 (35.0, 35.7) 39.4 (39.3, 39.4) −4.1 (−4.4, −3.8)
45–49 23,795 125 5.3 569,618 1811 3.2 31.2 (30.9, 31.4) 34.8 (34.7, 34.9) −3.6 (−3.8, −3.4)
50–54 36,860 300 8.1 537,661 2368 4.4 26.9 (26.7, 27.1) 30.3 (30.3, 30.4) −3.4 (−3.6, −3.2)
55–59 48,318 559 11.6 460,249 3200 7.0 23.0 (22.8, 23.1) 26.0 (25.9, 26.0) −3.0 (−3.2, −2.8)
60–64 58,216 990 17.0 408,713 4348 10.6 19.2 (19.0, 19.3) 21.8 (21.7, 21.9) −2.6 (−2.8, −2.4)
65–69 65,217 1546 23.7 363,325 6118 16.8 15.7 (15.5, 15.8) 17.8 (17.8, 17.9) −2.1 (−2.3, −1.9)
70–74 55,740 2246 40.3 255,444 7160 28.0 12.3 (12.2, 12.4) 14.2 (14.1, 14.2) −1.9 (−2.0, −1.8)
75–79 47,135 2991 63.5 193,469 8779 45.4 9.5 (9.4, 9.6) 10.9 (10.9, 11.0) −1.4 (−1.5, −1.3)
80–84 29,732 2978 100.2 127,063 9812 77.2 7.2 (7.0, 7.3) 8.1 (8.0, 8.2) −0.9 (−1.0, −0.8)
85–89 12,696 2076 163.5 64,202 8810 137.2 5.3 (5.2, 5.4) 5.8 (5.7, 5.8) −0.5 (−0.6, −0.4)
Women
40–44 9116 30 3.3 568,674 776 1.4 37.2 (36.8, 37.5) 42.6 (42.6, 42.7) −5.4 (−5.8, −5.0)
45–49 15,936 73 4.6 612,448 1190 1.9 32.7 (32.5, 33.0) 37.9 (37.9, 38.0) −5.2 (−5.5, −4.9)
50–54 23,908 174 7.3 577,364 1751 3.0 28.4 (28.2, 28.7) 33.3 (33.2, 33.3) −4.9 (−5.2, −4.6)
55–59 31,453 302 9.6 500,295 2322 4.6 24.4 (24.2, 24.6) 28.7 (28.7, 28.8) −4.3 (−4.5, −4.1)
60–64 38,141 530 13.9 450,705 3202 7.1 20.5 (20.3, 20.7) 24.4 (24.3, 24.4) −3.9 (−4.1, −3.7)
65–69 44,864 999 22.3 415,240 4529 10.9 16.8 (16.6, 16.9) 20.1 (20.1, 20.2) −3.3 (−3.5, −3.1)
70–74 46,212 1523 33.0 318,672 6036 18.9 13.5 (13.3, 13.6) 16.1 (16.1, 16.2) −2.6 (−2.7, −2.5)
75–79 45,181 2433 53.8 264,813 8592 32.4 10.4 (10.3, 10.5) 12.5 (12.4, 12.5) −2.1 (−2.2, −2.0)
80–84 33,888 2861 84.4 200,719 11,853 59.1 7.9 (7.8, 8.0) 9.3 (9.2, 9.3) −1.4 (−1.5, −1.3)
85–89 18,174 2546 140.1 125,136 13,454 107.5 5.8 (5.7, 5.9) 6.6 (6.6, 6.6) −0.8 (−0.9, −0.7)
a Difference calculated as: type 2 diabetes cohort life expectancy minus type 2 diabetes-free population life expectancy; negative values indicate lower
life expectancy in type 2 diabetes cohort
LE, life expectancy; P-Y, person-years
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are generally lower in absolute terms (i.e. closer to zero) in men
than in women, especially at the more deprived end of the SES
spectrum (Fig. 2a and Fig. 2b). The study’s second objective
was to assess whether the patterns of SES-related differences in
life expectancy among people with type 2 diabetes are similar
to those evident in a general population. For men, Fig. 3a
suggests that the difference in life expectancy between the
most- and least-deprived groups with type 2 diabetes is consis-
tently significantly lower (in absolute terms) for all age inter-
vals than that in the corresponding stratum of the type 2
diabetes-free population. That is, the SES-related difference
in mortality risk observed in the ‘general’ male population
appears to be attenuated in those with type 2 diabetes. For
women, (Fig. 3b) the position is different: in most age intervals,
the SES-related contrast in life expectancy for those with type 2
diabetes is not significantly different from that observed in the
type 2 diabetes-free population (as indicated by overlappingCIs).
Two strengths of the study may be highlighted. First, the
use of whole-population data avoids many of the biases which
may potentially arise in studies based on limited samples, for
example, people resident in a specific, relatively small geo-
graphical area. An example of the latter is provided by the
previously cited investigation reported by Perna et al [17].
This study, which focused on socioeconomic differences in
life expectancy among people with diabetes, used data for
the Augsburg region of Bavaria (Germany). The authors of
this study describe their cohort as a sample ‘whose population
structure reflects that of Germany as a whole’ (Perna et al [17]
p. 2), but this is obviously no substitute for having access (as
in the study reported here) to whole-population data. Indeed,
Perna et al openly acknowledge in their Discussion biases
attributable to the composition of their sample. A second
strength of the present study relates to the definition of diabe-
tes status. While some studies in the area of diabetes and mor-
tality have relied on self-reporting of the disease, the SCI-
Diabetes registry provides a reasonably robust, clinically
confirmed representation of diabetes status.
Against these strengths, limitations of the investigation re-
ported here are acknowledged. Using an area-based measure of
SES does not reliably attribute SES to individuals. However,
SIMD is based on a small average population of about 800
people. SIMD is believed to portray individual SES adequately
for health-related research in Scotland, and area-based mea-
sures are increasingly used internationally to assess inequalities
Fig. 1 Life expectancy in men
(a) and women (b) for the type 2
diabetes cohort (white symbols)
and type 2 diabetes-free
population (black symbols) in
Scotland, period 2012–2014,
stratified by SIMD quintile
(Q1 = most deprived). The
horizontal axis shows the
midpoint of age interval (e.g. age
interval 40–45 is plotted at 42).
The vertical axis shows life
expectancy (years). Error bars
represent 95% CI
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in health and mortality [28]. A second limitation relates to the
fundamental nature of life tables. The life table as employed
here estimates the period life expectancy, defined by the UK
Office for National Statistics as ‘the average number of years a
person would live, if he or she experienced the particular area’s
age-specific mortality rates for that time period throughout his
or her life’ [29]. While this measure is commonly used to com-
pare life expectancy between groups or countries or over time,
the assumption of static mortality rates is obviously unrealistic.
The alternative is to estimate cohort life expectancy, which
essentially either uses data for a cohort that has been followed
up to complete mortality or else focuses on synthetic cohorts
wherein assumptions are made about the future patterns in mor-
tality rates and differentials. Such an approach has the advan-
tage of avoiding the simplistic assumption that life expectancy
will not change in future but has the drawback that it is very
susceptible to arbitrary assumptions about future rates. A third
limitation relates to the possible misclassification of type of
diabetes; specifically, the potential for people with insulin-
treated type 2 diabetes to be labelled as having type 1 disease.
Where this occurs, these individuals (who have a relatively high
risk of mortality) will be included in the type 2 diabetes-free
population and thus obscure the ‘true’ contrast between those
with and without type 2 diabetes. While such misclassification
cannot be ruled out, the algorithm used in SCI-Diabetes to
define type of diabetes has been extensively refined and is
believed to be robust. Consequently, instances of misclassifica-
tion are likely to be rare.
Two aspects of the study’s findings merit further comment.
First, although a life-expectancy deficit associated with type 2
diabetes is observed at all ages, its absolute magnitude (the
number of expected years ‘lost’) is relatively small, especially
at older ages during which type 2 diabetes becomes more
common. A meta-analysis cited earlier identified an approxi-
mate doubling ofmortality risk in people with diabetes [3], but
when viewed from the alternative age-specific perspective
provided by life expectancy, the increased ‘vulnerability to
death’ associated with type 2 diabetes is perhaps smaller than
might intuitively have been expected. A second prominent
feature of the results is that patterns of the absolute differences
in life expectancy associated with type 2 diabetes, and the
respective sizes of the differences associated with type 2 dia-
betes and with inequality (SES), vary markedly by sex. In
men, the difference in life expectancy associated with type 2
Fig. 2 Difference in life
expectancy in men (a) and
women (b) in Scotland, period
2012–2014; data are calculated as
the value for type 2 diabetes
cohort minus value for type 2
diabetes-free population; negative
values indicate lower life
expectancy in the type 2 diabetes
cohort. Data are stratified by
SIDM quintile (Q1 = most
deprived). The horizontal axis
shows the midpoint of age
interval (e.g. age interval 40–45 is
plotted at 42). The vertical axis
shows the difference in life
expectancy (years); the dashed
horizontal line marks zero (‘no
difference’). Error bars represent
95% CI
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diabetes (Fig. 2a) is smaller than that associated with depriva-
tion (more specifically, the contrast between the most- and
least-deprived population quintiles, Fig. 3a). This feature
is largely absent in women. Given the pervasiveness of
socially patterned mortality found in innumerable societies
and contexts, the substantial association of SES with life ex-
pectancy in men is unsurprising, and reinforces the message
that for men with diabetes (as for many other clinical entities),
improvement of mortality prospects will demand not only
effective management of the condition but also the develop-
ment of more general strategies to reduce inequality. However,
reasons for the between-sex difference require consideration.
A major contributor to premature death in people with diabe-
tes is CHD, and previous work suggests that diabetes is a more
influential risk factor for coronary death in women than in
men [30]. However, Kanaya et al reported that the elevation
of CHD mortality in women with diabetes relative to that in
men with the disease is mediated by established cardiovascu-
lar disease risk factors, and largely disappears after adjustment
for these factors [31]. It may therefore be that sex-related
differences in the associations between diabetes and life ex-
pectancy (notably, the respective effect sizes associated with
type 2 diabetes and with SES) are wholly or partly explained
by differential patterns of established cardiovascular disease
risk factors or comorbidity (with potential variation by sex
and/or SES and/or diabetes status). We were not able to test
this hypothesis because risk factor data are not available for
people without diabetes in this study.
Scope exists for further work to expand understanding of
the relationships that link diabetes, SES, and life expectancy,
including the role of differing patterns of cardiovascular
disease risk factors and comorbidities. The study considered
only the presence or absence of type 2 diabetes, but took no
account of the possible effect of duration of diabetes on the
observed associations. For example, a person aged 55 might
have recently been diagnosed with the disease, or alternatively
might have lived with the condition for decades. Previous
work has demonstrated that duration of diabetes appears to
modify the association between type 2 diabetes and mortality
[4]. It is therefore reasonable to hypothesise that the reduction
in life expectancy for those with type 2 diabetes observed in
this study may be underestimated for individuals with long-
standing diabetes, and overestimated for those recently diag-
nosed with the condition. Further work is required to clarify
this. A related question, again unanswered in this investiga-
tion, is whether age at onset of diabetes modifies the relation-
ship of the disease with life expectancy. The results presented
here suggest that for older people the absolute reduction in life
Fig. 3 Difference in life
expectancy in men (a) and
women (b) in Scotland, period
2012–2014; data are calculated as
the value for most-deprived
minus value for least-deprived
SIMD quintile; negative values
indicate lower life expectancy in
the most-deprived quintile. White
symbols, type 2 diabetes cohort;
black symbols, type 2 diabetes-
free population. The horizontal
axis shows the midpoint of age
interval (e.g. age interval 40–45 is
plotted at 42). The vertical axis
shows the difference in life
expectancy (years); the dashed
horizontal line marks zero (‘no
difference’). Error bars represent
95% CI
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expectancy associated with type 2 diabetes is small, but intro-
ducing age at onset into consideration would reveal whether
onset of diabetes at more advanced ages exerts any material
effect (in a statistical, not causal, sense) on life expectancy at all.
In conclusion, we have shown that type 2 diabetes is asso-
ciated with reductions in life expectancy in most subgroups of
the population of Scotland and that the size of the reduction
varies by age, sex and SES. Even the largest differences in life
expectancy associated with type 2 diabetes are smaller than
may have been expected from relative risks of mortality asso-
ciated with type 2 diabetes that we and others have previously
reported. However, these findings suggest that increasing
prevalence of diabetes will contribute to slower improvements
in population life expectancy over time. Increasing incidence
of type 2 diabetes in young people can be expected to have a
particularly detrimental effect on life expectancy.
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